These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37227597)

  • 21. Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression.
    Zheng W; Zhou YL; Liu WJ; Wang CY; Zhan YN; Li HQ; Chen LJ; Li MD; Ning YP
    J Psychiatr Res; 2018 Nov; 106():61-68. PubMed ID: 30278319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neural connectivity moderators and mechanisms of ketamine treatment among treatment-resistant depressed patients: a randomized controlled trial.
    Rengasamy M; Mathew S; Howland R; Griffo A; Panny B; Price R
    EBioMedicine; 2024 Jan; 99():104902. PubMed ID: 38141395
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mitochondrial modulators in the treatment of bipolar depression: a systematic review and meta-analysis.
    Liang L; Chen J; Xiao L; Wang Q; Wang G
    Transl Psychiatry; 2022 Jan; 12(1):4. PubMed ID: 35013098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Esketamine and Psilocybin-The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review.
    Psiuk D; Nowak EM; Dycha N; Łopuszańska U; Kurzepa J; Samardakiewicz M
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232748
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes.
    McGirr A; Berlim MT; Bond DJ; Fleck MP; Yatham LN; Lam RW
    Psychol Med; 2015 Mar; 45(4):693-704. PubMed ID: 25010396
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NRX-101 (D-cycloserine plus lurasidone) vs. lurasidone for the maintenance of initial stabilization after ketamine in patients with severe bipolar depression with acute suicidal ideation and behavior: a randomized prospective phase 2 trial.
    Nierenberg A; Lavin P; Javitt DC; Shelton R; Sapko MT; Mathew S; Besthof RE; Javitt JC
    Int J Bipolar Disord; 2023 Aug; 11(1):28. PubMed ID: 37573534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ketamine administration in depressive disorders: a systematic review and meta-analysis.
    Fond G; Loundou A; Rabu C; Macgregor A; Lançon C; Brittner M; Micoulaud-Franchi JA; Richieri R; Courtet P; Abbar M; Roger M; Leboyer M; Boyer L
    Psychopharmacology (Berl); 2014 Sep; 231(18):3663-76. PubMed ID: 25038867
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neural Correlates of the DEEPP (Anti-suicidal Response to Ketamine in Treatment-Resistant Bipolar Depression) Study: Protocol for a Pilot, Open-Label Clinical Trial.
    Knyahnytska Y; Zomorrodi R; Kaster T; Voineskos D; Trevizol A; Blumberger D
    JMIR Res Protoc; 2023 Jan; 12():e41013. PubMed ID: 36573651
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective.
    Hashimoto K
    Psychiatry Clin Neurosci; 2019 Oct; 73(10):613-627. PubMed ID: 31215725
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New investigational agents for the treatment of major depressive disorder.
    Pochwat B; Krupa AJ; Siwek M; Szewczyk B
    Expert Opin Investig Drugs; 2022 Oct; 31(10):1053-1066. PubMed ID: 35975761
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lithium and Valproate Levels Do Not Correlate with Ketamine's Antidepressant Efficacy in Treatment-Resistant Bipolar Depression.
    Xu AJ; Niciu MJ; Lundin NB; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Machado-Vieira R; Zarate CA
    Neural Plast; 2015; 2015():858251. PubMed ID: 26137324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical highlights in bipolar depression: focus on atypical antipsychotics.
    Calabrese JR; Elhaj O; Gajwani P; Gao K
    J Clin Psychiatry; 2005; 66 Suppl 5():26-33. PubMed ID: 16038599
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of scopolamine compared to placebo in individuals with bipolar disorder who are experiencing a depressive episode (SCOPE-BD): study protocol for a randomised double-blind placebo-controlled trial.
    Miravalles C; Kane R; McMahon E; McDonald C; Cannon DM; Hallahan B
    Trials; 2022 Apr; 23(1):339. PubMed ID: 35461262
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
    Diazgranados N; Ibrahim L; Brutsche NE; Newberg A; Kronstein P; Khalife S; Kammerer WA; Quezado Z; Luckenbaugh DA; Salvadore G; Machado-Vieira R; Manji HK; Zarate CA
    Arch Gen Psychiatry; 2010 Aug; 67(8):793-802. PubMed ID: 20679587
    [TBL] [Abstract][Full Text] [Related]  

  • 35. International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators.
    Price RB; Kissel N; Baumeister A; Rohac R; Woody ML; Ballard ED; Zarate CA; Deakin W; Abdallah CG; Feder A; Charney DS; Grunebaum MF; Mann JJ; Mathew SJ; Gallagher B; McLoughlin DM; Murrough JW; Muthukumaraswamy S; McMillan R; Sumner R; Papakostas G; Fava M; Hock R; Phillips JL; Blier P; Shiroma P; Šóš P; Su TP; Chen MH; Tiger M; Lundberg J; Wilkinson ST; Wallace ML
    Mol Psychiatry; 2022 Dec; 27(12):5096-5112. PubMed ID: 36071111
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-inflammatory agents in the treatment of bipolar depression: a systematic review and meta-analysis.
    Rosenblat JD; Kakar R; Berk M; Kessing LV; Vinberg M; Baune BT; Mansur RB; Brietzke E; Goldstein BI; McIntyre RS
    Bipolar Disord; 2016 Mar; 18(2):89-101. PubMed ID: 26990051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Double-Blinded, Randomized, Placebo-Controlled Sub-Dissociative Dose Ketamine Pilot Study in the Treatment of Acute Depression and Suicidality in a Military Emergency Department Setting.
    Burger J; Capobianco M; Lovern R; Boche B; Ross E; Darracq MA; McLay R
    Mil Med; 2016 Oct; 181(10):1195-1199. PubMed ID: 27753551
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Efficacy of atypical antipsychotics in depressive syndromes].
    Quintin P; Thomas P
    Encephale; 2004; 30(6):583-9. PubMed ID: 15738862
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advancing bipolar disorder: key lessons from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).
    Parikh SV; LeBlanc SR; Ovanessian MM
    Can J Psychiatry; 2010 Mar; 55(3):136-43. PubMed ID: 20370963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative effectiveness of esketamine in the treatment of anhedonia in bipolar and unipolar depression.
    Delfino RS; Del-Porto JA; Surjan J; Magalhães E; Sant LCD; Lucchese AC; Tuena MA; Nakahira C; Fava VAR; Steglich MS; Barbosa MG; Sarin LM; Lacerda ALT
    J Affect Disord; 2021 Jan; 278():515-518. PubMed ID: 33017679
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.